77658-84-5 Usage
Uses
Used in Oncology:
Antineoplaston A10 is used as a potential antineoplastic agent for its ability to inhibit the growth and spread of various types of cancer. It is currently being investigated in clinical trials for its potential treatment of brain tumors and other malignancies.
Used in Clinical Research:
Antineoplaston A10 is used as a subject of clinical trials to further understand its mechanism of action, safety, and effectiveness in treating cancer. More research is needed to determine its full potential and to establish its role in cancer therapy.
Used in Drug Development:
Antineoplaston A10 is used in the development of new cancer treatments, as its unique properties and potential antineoplastic effects make it a promising candidate for further study and potential incorporation into novel therapeutic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 77658-84-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,7,6,5 and 8 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 77658-84:
(7*7)+(6*7)+(5*6)+(4*5)+(3*8)+(2*8)+(1*4)=185
185 % 10 = 5
So 77658-84-5 is a valid CAS Registry Number.
InChI:InChI=1/C13H14N2O3/c16-11-7-6-10(13(18)15-11)14-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,17)(H,15,16,18)
77658-84-5Relevant academic research and scientific papers
SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION
-
Page/Page column 171; 181, (2017/10/11)
Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.
ACID ADDITION SALTS OF LENALIDOMIDE
-
Page/Page column 30, (2011/05/11)
The invention relates to acid addition salts of lenalidomide as well as to desirable polymorphic forms of lenalidomide hydrogen sulfate. Furthermore, the invention provides a process for producing acid addition salts of lenalidomide, which optionally can comprise a further step producing lenalidomide in form of the free base.
